Alphabetical listing of all products

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Prices
  • 5 mg - 140 EUR
  • 25 mg - 560 EUR
  • 100 mg - 1680 EUR

Fedratinib (TG101348)

TG101348 is a potent and selective ATP-competitive JAK2 inhibitor with an IC50 of 3 nM; it is active also towards the JAK2 V617F mutant. TG101348 also inhibits the Flt3 and Ret kinases with IC50 values of 15 and 48 nM, respectively. It exhibits significantly less activity against other tyrosine kinases, including JAK3 (IC50=169 nM). In treated cells, it blocks downstream cellular signalling (JAK-STAT), suppressing proliferation and inducing apoptosis. It is currently being developed for the treatment of patients with myeloproliferative diseases including myelofibrosis.

catalogue number: T110
synonyms: TG-101348
CAS: 936091-26-8
MW: 524.68 g/mol

References
Leukemia. 2008 Sep;22(9):1790-2. PMID: 18354492
Cancer Cell. 2008 Apr;13(4):311-20. PMID: 18394554